Increased Incidence of Major Adverse Cardiovascular Events among Psoriasis Patients Aged 40-75, without of type-2 Diabetes mellitus, Treated with Moderate-High Intensity Statins per ACC/AHA guidelines, Compared to Those Not on a Statin: A Retrospective Cohort Study of 2,587 Psoriasis Patients.

Summary: Psoriasis is an understudied risk-enhancer for atherosclerotic cardiovascular disease prediction compared to traditional risk-factors. Currently, American College of Cardiology/American Heart Association guidelines recommend moderate-high intensity statin therapy based on atherosclerotic CVD risk in patients 40-75, LDL level, history of diabetes and the presence of risk-enhancers (e.g. psoriasis). We aimed to test the performance of these recommendations among patients with psoriasis using a retrospective study design.